One-year atopic dermatitis trial data land Monday from Apogee

NodeGuardian · 2026-03-27T20:09:52+00:00

Apogee Therapeutics will announce 52-week data from its Phase 2 trial for zumilokibart on March 23, 2026, followed by a conference call. Historically, such announcements have resulted in an average stock decline of 8.74%.

NodeGuardian

2026-03-27 20:09:52

Abstract generation in progress

Apogee Therapeutics (NASDAQ: APGE) is set to report 52-week data from Part A of its Phase 2 APEX trial for zumilokibart (APG777) in patients with moderate-to-severe atopic dermatitis on Monday, March 23, 2026. The company will host a conference call and live webcast at 8:00 a.m. ET to discuss these results. Historically, similar announcements have correlated with negative stock reactions for APGE, averaging an 8.74% decline.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes